

**Amendments to the Claims**

Please amend the claims as indicated below.

1-11. (Cancelled).

12. (Currently amended) The method of Claim ~~44~~ 39, wherein:

$R_{h1}$  and  $R_{h2}$  are independently H and Et.

13. (Currently amended) The method of Claim ~~44~~ 39, wherein:

$R_{h1}$  and  $R_{h2}$  are independently H and n-Pr.

14. (Currently amended) The method of Claim ~~44~~ 39, wherein:  $R_{h1}$  and  $R_{h2}$  are independently H and i-Bu.

15. (Currently amended) The method of Claim ~~44~~ 39, wherein:  $R_{h1}$  and  $R_{h2}$  are independently H and  $\text{CH}_2\text{OH}$ .

16. (Currently amended) The method of Claim ~~44~~ 39, wherein:  $R_{h1}$  and  $R_{h2}$  are independently H and n-Bu.


17. (Currently amended) The method of Claim ~~44~~ 39, wherein:  $R_{h1}$  and  $R_{h2}$  are independently H and Me.

18. (Currently amended) The method of Claim ~~44~~ 39, wherein:  $R_{h1}$  and  $R_{h2}$  are independently H and  $(\text{CH}_2)_n\text{N}(\text{Me})_2$ , wherein n is from 1 to 6.

19-38. (Cancelled).

Please add the following new Claim 39, as follows:

39. (New) A method of inhibiting angiogenesis comprising administering to an endothelial cell an angiogenesis inhibiting amount of a compound of the general formula:



wherein, R<sub>h1</sub> and R<sub>h2</sub> are independently H and a compound selected from Et, n-Pr, i-Bu, CH<sub>2</sub>OH, n-Bu, Me or (CH<sub>2</sub>)<sub>n</sub>N(Me)<sub>2</sub>, wherein n is from 1 to 6, provided that both R<sub>h1</sub> and R<sub>h2</sub> are not H, and wherein all monosubstituted substituents have either an  $\alpha$  or  $\beta$  configuration.